Lord, Abbett & Co
MACK

Lord, Abbett & Co’s Merrimack Pharmaceuticals, Inc. MACK Stock Holding History

Lord, Abbett & Co’s Portfolio MACK Stock Details MACK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q1 		– Sell
-69,168
Closed -$6.15M – 994
2014
Q4 		$6.15M Sell
69,168
-9,191
-12% -$670K 0.02% 693
2014
Q3 		$5.41M Buy
+78,359
New +$4.19M 0.01% 730

Other funds holding MACK

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Westfield Capital Management
Westfield Capital Management Boston, Massachusetts $23.8B AUM 49.45% 1-Year Est. Return
TCIM
TIAA CREF Investment Management New York $141B AUM 14.18% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
LIM
Lagoda Investment Management New York $162M AUM 49.7% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return
TA
Teachers Advisors New York $81.7B AUM 13.62% 1-Year Est. Return

Lord, Abbett & Co's MACK Position: Q1 2015 in Review

Lord, Abbett & Co sold out of Merrimack Pharmaceuticals, Inc. (MACK) in Q1 2015, closing a stake of 69,168 shares — an estimated $6.15M sold.

Lord, Abbett & Co first reported a position in MACK in Q3 2014 and held it in 2 quarters. The position peaked at $6.15M in Q4 2014. 152 funds tracked by Wall St. Rank hold MACK as of Q1 2015.

  • Lord, Abbett & Co reported no remaining Merrimack Pharmaceuticals, Inc. position as of Q1 2015 after selling out during the quarter.
  • Lord, Abbett & Co sold 69,168 Merrimack Pharmaceuticals, Inc. shares in Q1 2015, an estimated $6.15M.
  • Lord, Abbett & Co first reported a position in Merrimack Pharmaceuticals, Inc. in Q3 2014 and held it in 2 quarters.
  • Lord, Abbett & Co's Merrimack Pharmaceuticals, Inc. position peaked at $6.15M in Q4 2014.
  • 152 funds tracked by Wall St. Rank held Merrimack Pharmaceuticals, Inc. as of Q1 2015.

Based on Lord, Abbett & Co's 13F filing for Q1 2015, filed 15 May 2015.